Bioventus Inc. (NASDAQ:BVS) is recommended as one of the best medical device stocks to buy by analysts. Craig-Hallum analyst Chase Knickerbocker reiterated a Buy rating with a price target of $15.00 after Bioventus reported fiscal Q2 results on August 6, showing reported revenue of $147.7 million and organic revenue growth of 6.2%.

Bioventus Inc. (NASDAQ:BVS) reported diluted earnings per share of $0.11 for Q2, a significant improvement from a diluted loss per share of $0.40 in the prior-year period. The company also reported cash from operations of $25.9 million and non-GAAP earnings of $0.21 per share.

Bioventus Inc. (NASDAQ:BVS) is a medical technology company specializing in orthobiologic products for musculoskeletal conditions. While BVS shows investment potential, some AI stocks may offer greater upside with less risk. For those seeking undervalued AI stocks, a free report on the best short-term AI stock is available.

Read more at Yahoo Finance: Craig-Hallum Reiterates a Buy Rating on Bioventus (BVS), Sets a $15 PT